{"url_path":"/sec/sldb/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-219337-index.html","accession_number":"0001193125-26-219337","cik":"0001707502","ticker":"SLDB","issuer_name":"Solid Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1707502/0001193125-26-219337-index.html","primary_entity_key":"0001707502","primary_entity_name":"Solid Biosciences Inc."},"word_count":444,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n \n\n \n\n \n\n \n\n4.1\n\n[Form of Unregistered Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2026).](https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/d81855dex41.htm)\n\n \n\n \n\n10.1†*\n\n[Summary of Non-Employee Director Compensation Program](sldb-ex10_1.htm)\n\n \n\n \n\n10.2\n\n[Form of Securities Purchase Agreement, dated March 6, 2026, by and among the Company and the other](https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/d81855dex101.htm)\n\n[parties thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2026).](https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/d81855dex101.htm)\n\n \n\n \n\n10.3\n\n \n\n[Form of Registration Rights Agreement, dated March 6, 2026, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2026).](https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/d81855dex102.htm)\n\n \n\n \n\n \n\n10.4†\n\n[Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith, as amended by the First Amendment to Executive Chair Agreement, effective September 30, 2022, Second Amendment to the Executive Chair Agreement, effective January 1, 2024, Third Amendment to the Executive Chair Agreement, effective January 6, 2025 and Fourth Amendment to Executive Chair Agreement, effective January 1, 2026 (incorporated by reference to Exhibit 10.14 to the Registrant’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19, 2026).](https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-ex10_14.htm)\n\n \n\n \n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](sldb-ex31_1.htm)\n\n \n\n \n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](sldb-ex31_2.htm)\n\n \n\n \n\n32.1**\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](sldb-ex32_1.htm)\n\n \n\n \n\n32.2**\n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](sldb-ex32_2.htm)\n\n \n\n \n\n101.INS\n\nInline XBRL Instance Document\n\n \n\n \n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema Document\n\n \n\n \n\n104\n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n \n\n* Filed herewith.\n\n** Furnished herewith.\n\n† Indicates management contract or compensatory plan.\n\n86\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nSolid Biosciences Inc.\n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\nBy:\n\n \n\n/s/ Alexander Cumbo\n\nAlexander Cumbo\n\nPresident and Chief Executive Officer\n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\n \n\nBy:\n\n/s/ Kevin Tan\n\n \n\nKevin Tan\n\nChief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n \n\n87"}